Mavenclad

A sublingual formulation of cladribine, which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties to its name-brand counterpart. That’s according to preclinical data announced by BioNxt Solutions, the formulation’s developer, in a company press release.

A short course of treatment with Mavenclad (cladribine) can provide long-term reductions in disease activity and disability progression for as long as four years in adults with highly active, relapsing forms of multiple sclerosis (MS), according to new data from the MAGNIFY-MS studies. The majority of patients had…

England’s National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of Mavenclad (cladribine) in people with aggressive relapsing-remitting multiple sclerosis (RRMS) in ways that should help eligible patients be able to access the medication sooner. The new guidelines have less stringent…

The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with active relapsing forms of multiple sclerosis (MS), as defined by clinical or imaging features. This decision made the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) the first to…

Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in people with highly active relapsing multiple sclerosis (MS), according to a final analysis of data from the Phase 4 CLARIFY-MS study. Mavenclad is an oral medication approved for people with…

ChariotMS, the world’s first clinical trial to test whether Mavenclad (cladribine) can slow the worsening of upper limb function in people with progressive multiple sclerosis (MS), has now enrolled 100 participants. The announcement means the Phase 2 trial (NCT04695080) has reached 50% of its target recruitment goal.

Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced patients’ relapse rates and the development of new lesions while keeping disability stable over two years, according to a real-world study in Kuwait. Among patients who completed the two courses…

Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups — but…

The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS), according to real-world data from the CLASSIC-MS study. More than half of those who received the oral therapy in the clinical trials that supported…

Early treatment with Mavenclad (cladribine) or monoclonal antibodies is more likely to control symptoms in people with highly active multiple sclerosis (MS), a study in Argentina suggests. Highly active disease usually is considered when frequent relapses occur and there is an increasing burden of brain magnetic resonance imaging…

Aiming to promote equitable access to multiple sclerosis (MS) treatments worldwide, an international MS alliance is asking that three disease-modifying therapies (DMTs) be added to the World Health Organization’s (WHO) list of essential medicines. Inclusion on the WHO list is considered an important if “initial” step in assuring that helpful treatments…

In December 2019, I was stopped in my tracks, or rather wheels, as I was about to have my third infusion of Ocrevus (ocrelizumab), the multiple sclerosis disease-modifying therapy (DMT) that I’d been taking every six months for the past year. My neurologist had decided just a few…

The safety and efficacy of the approved multiple sclerosis (MS) therapy Mavenclad (cladribine) in a real-world group of patients were similar to what had been demonstrated in clinical trials, a new study reports. Among 243 people with relapsing-remitting multiple sclerosis (RRMS), more than 60% showed no…

People with multiple sclerosis (MS) who are treated with Mavenclad (cladribine) are less likely to experience a disease relapse than those who are treated with Gilenya (fingolimod), Tecfidera (dimethyl fumarate), or Aubagio (teriflunomide), according to an analysis of real-world data. The findings were presented at the Americas Committee…

As usual, I’ve gone for what I hope to be an intriguing headline, because you’ve got to grab a reader by any means necessary. If you’ve read this far, I’m winning! This saga goes back well over a year, when my neurologist suggested I participate in a clinical trial for…

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Mavenclad…

Trial Will Test Mavenclad for Advanced Progressive MS I often think that researchers have forgotten about people whose MS has progressed to an advanced stage. But MS patients who have moved into a wheelchair deserve treatment with a disease-modifying therapy as much as those who are just beginning their…

After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study, ChariotMS (NCT04695080), aims to…

Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds I regularly see people posting on social media about having a rash or itchy skin, or losing hair while taking Mavenclad. Researchers in this study say these side effects aren’t mentioned in the risk management plans for this disease-modifying therapy. Therefore,…

Skin reactions are common among relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated in a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…

Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…

Treatment with Mavenclad (clabridine) reduces the frequency of relapses in people with relapsing-remitting multiple sclerosis (RRMS), with benefits appearing to be evident two years after patients stopped taking the treatment, new data suggest. These findings were in the study, “Analysis of frequency and severity of relapses…

Are you being treated with a disease-modifying therapy (DMT) and wondering how it might affect the efficacy of an mRNA-based COVID-19 vaccine? If so, a recent study may provide some clarity. The study, published in Therapeutic Advances in Neurological Disorders, looked at 125 MS patients either being treated with…

Isn’t it just like me to start my column with a physics analogy that is already confusing? Please stick with me, as all will be revealed. My point is that if a black hole is big enough, you might slip through its event horizon without even noticing. There would…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. A majority of the relapsing-remitting multiple sclerosis (RRMS) patients given Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…

Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3 trial data found. A demyelinating event occurs when myelin — the protective coating around nerve fibers — experiences damage; this…

An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities. Patients reliant on wheelchairs or aids to walk even short distances generally have…